Literature DB >> 29143097

[Concurrent once-daily or twice-daily chemoradiotherapy in limited-stage small-cell lung cancer?]

Susanne Frosch1, Esther G C Troost2,3,4,5.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29143097     DOI： 10.1007/s00066-017-1234-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  12 in total

1.  70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

Authors:  Jeffrey A Bogart; James E Herndon; Alan P Lyss; Dorothy Watson; Antonius A Miller; Michael E Lee; Andrew T Turrisi; Mark R Green
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

2.  [Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation].

Authors:  Thomas Herrmann; Michael Baumann
Journal:  Strahlenther Onkol       Date:  2005-02       Impact factor: 3.621

Review 3.  Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Madelon Pijls-Johannesma; Dirk De Ruysscher; Johan Vansteenkiste; Arnold Kester; Isabelle Rutten; Philippe Lambin
Journal:  Cancer Treat Rev       Date:  2007-05-21       Impact factor: 12.111

4.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

Authors:  A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

Review 5.  Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy.

Authors:  S M Bentzen; A C Ruifrok; H D Thames
Journal:  Radiother Oncol       Date:  1996-02       Impact factor: 6.280

6.  Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.

Authors:  M I Saunders; P J Hoskin; K Pigott; M E Powell; K Goodchild; S Dische; J Denekamp; M R Stratford; M F Dennis; A M Rojas
Journal:  Radiother Oncol       Date:  1997-11       Impact factor: 6.280

Review 7.  Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.

Authors:  Young Kwang Chae; Alan Pan; Andrew A Davis; Nisha Mohindra; Maria Matsangou; Victoria Villaflor; Francis Giles
Journal:  Clin Lung Cancer       Date:  2016-07-09       Impact factor: 4.785

8.  The hazard of accelerated tumor clonogen repopulation during radiotherapy.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

9.  Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.

Authors:  Edurne Arriola; Matthew Wheater; Ian Galea; Nadia Cross; Tom Maishman; Debbie Hamid; Louise Stanton; Judith Cave; Tom Geldart; Clive Mulatero; Vannessa Potter; Sarah Danson; Pennella J Woll; Richard Griffiths; Luke Nolan; Christian Ottensmeier
Journal:  J Thorac Oncol       Date:  2016-06-11       Impact factor: 15.609

10.  Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.

Authors:  Jing Zhang; Min Fan; Di Liu; Kuai-Le Zhao; Kai-Liang Wu; Wei-Xin Zhao; Zheng-Fei Zhu; Xiao-Long Fu
Journal:  Radiat Oncol       Date:  2017-03-11       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.